Kandarp Patel, MD
Cardiology · Jackson, TNNPI 1235195561
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.3% of the total across 410 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 41 manufacturers, the largest accounting for just 19.6% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $1,573 and has fallen 92.5% since, to $119 in 2025.
Across 410 payments — averaging $15.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$1K
- Boehringer Ingelheim$595
- Novo Nordisk$531
- Sanofi-aventis U.S. LLC$488
- Amgen$417
- Kowa Pharmaceuticals America, Inc.$365
- plus $3K from 35 others
What the payments were for
- Food & beverage$6,12699%
- Education$431%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 75 | $1,211 |
| Boehringer Ingelheim | 44 | $595 |
| Novo Nordisk | 39 | $531 |
| Sanofi-aventis U.S. LLC | 37 | $488 |
| Amgen(2 entities) | 26 | $417 |
| Kowa Pharmaceuticals America, Inc. | 18 | $365 |
| Novartis | 28 | $356 |
| Bayer | 18 | $248 |
| GSK | 15 | $245 |
| Arbor Pharmaceuticals, Inc. | 16 | $241 |
| Pfizer | 16 | $236 |
| Esperion Therapeutics, Inc. | 11 | $193 |
| Johnson & Johnson | 10 | $161 |
| Lundbeck LLC | 6 | $109 |
| Eisai Inc. | 6 | $86 |
| Teva Pharmaceuticals USA, Inc. | 4 | $68 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $43 |
| Boston Scientific | 1 | $42 |
| Shield Therapeutics Inc | 3 | $42 |
| Bardy Diagnostics, Inc. | 5 | $40 |
| Mylan Specialty L.p. | 2 | $35 |
| LSI Solutions Inc | 2 | $33 |
| Astellas Pharma US Inc | 2 | $33 |
| Azurity Pharmaceuticals, Inc. | 2 | $32 |
| Abbott | 2 | $32 |
| E.r. Squibb & Sons, L.L.C. | 2 | $32 |
| Sanofi | 1 | $29 |
| Daiichi Sankyo Inc. | 2 | $29 |
| Medtronic | 2 | $26 |
| Redhill Biopharma Inc. | 2 | $22 |
| Mannkind Corporation | 1 | $17 |
| Philips North America LLC | 1 | $16 |
| AbbVie | 1 | $15 |
| Phathom Pharmaceuticals, Inc. | 1 | $14 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $14 |
| Gilead | 1 | $13 |
| CMP Pharma, Inc. | 1 | $12 |
| Merck | 1 | $12 |
| Biohaven Pharmaceuticals, Inc. | 1 | $12 |
| Lilly USA, LLC | 1 | $11 |
| Regeneron Healthcare Solutions, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
Too few cardiology providers in Tennesseeto place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 970 | $733,693 |
| EliquisApixaban | 783 | $628,683 |
| JardianceEmpagliflozin | 566 | $443,008 |
| OzempicSemaglutide | 403 | $407,444 |
| Repatha SureclickEvolocumab | 480 | $390,091 |
| MounjaroTirzepatide | 305 | $327,931 |
| XareltoRivaroxaban | 203 | $192,794 |
| TrulicityDulaglutide | 145 | $164,492 |
| Bydureon BciseExenatide Microspheres | 143 | $130,881 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 137 | $89,999 |
| LinzessLinaclotide | 121 | $88,522 |
| JanuviaSitagliptin Phosphate | 104 | $85,403 |
| CamzyosMavacamten | 11 | $83,269 |
| Repatha SyringeEvolocumab | 122 | $77,344 |
| Tresiba Flextouch U-100Insulin Degludec | 104 | $55,013 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga, Brilinta, Symbicort, Breztri Aerosphere | $1,211 | $800,2021,108 claims |
| PfizerEliquis | $236 | $628,683783 claims |
| Lilly USA, LLCMounjaro, Trulicity | $11 | $492,423450 claims |
| Novo NordiskOzempic, Rybelsus, Wegovy | $531 | $477,986449 claims |
| Boehringer IngelheimJardiance, Spiriva Respimat | $595 | $474,237619 claims |
| Johnson & JohnsonXarelto | $161 | $192,794203 claims |
| MerckJanuvia, Janumet Xr | $12 | $111,746152 claims |
| GSKTrelegy Ellipta, Anoro Ellipta | $245 | $111,684185 claims |
| AbbVieLinzess, Creon | $15 | $107,522132 claims |
| E.r. Squibb & Sons, L.L.C.Camzyos | $32 | $83,26911 claims |
| NovartisEntresto | $356 | $44,09754 claims |
| BayerKerendia | $248 | $28,68242 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few cardiology providers in Tennesseeon file to place this against a meaningful peer group, so we don't.
Other cardiology in Jackson
- Louis CunninghamJackson$3K
- Patricia ObiJackson$14
- Hal RosemanNashville$79K
- Andrew WatsonGermantown$1K
- Sathvika GaddamJohnson City$19
- Vianney VillaruzCrossville$0
- Howard ChuangMemphis$0
- Benjamin ByrdNashville$0
- Melissa Walton-ShirleyGallatin$0
- Jane FreedmanNashville$0
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.